288 related articles for article (PubMed ID: 17213504)
1. The way women perceive teratogenic risk.
Koren G
Can J Clin Pharmacol; 2007; 14(1):e10-6. PubMed ID: 17213504
[No Abstract] [Full Text] [Related]
2. 45 years later...where do we stand?
Benegbi M
Can J Clin Pharmacol; 2007; 14(1):e37-9. PubMed ID: 17213509
[No Abstract] [Full Text] [Related]
3. Drugs in pregnancy.
Koren G; Pastuszak A; Ito S
N Engl J Med; 1998 Apr; 338(16):1128-37. PubMed ID: 9545362
[No Abstract] [Full Text] [Related]
4. [Drug noxae as indications for pregnancy interruption].
Neubert D
Internist (Berl); 1978 May; 19(5):304-9. PubMed ID: 350801
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
Ornoy A
Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
[TBL] [Abstract][Full Text] [Related]
6. [Prospective OMEGA survey (Drug use-pregnancy relationship survey at the French Riviera)].
Spreux A; Chichmanian RM; Jean-Girard C; Nouchi J
Therapie; 1991; 46(5):369-72. PubMed ID: 1754980
[TBL] [Abstract][Full Text] [Related]
7. Fetal exposure to isotretinoin-an international problem.
Garcia-Bournissen F; Tsur L; Goldstein LH; Staroselsky A; Avner M; Asrar F; Berkovitch M; Straface G; Koren G; De Santis M
Reprod Toxicol; 2008 Jan; 25(1):124-8. PubMed ID: 18077132
[TBL] [Abstract][Full Text] [Related]
8. Challenges in drug use near term and during delivery.
Farine D
Can J Clin Pharmacol; 2007; 14(1):e29-33. PubMed ID: 17213507
[No Abstract] [Full Text] [Related]
9. Classification of drugs for teratogenic risk: an anachronistic way of counseling.
Merlob P; Stahl B
Teratology; 2002 Aug; 66(2):61-2. PubMed ID: 12210007
[No Abstract] [Full Text] [Related]
10. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools.
Uhl K; Trontell A; Kennedy D
Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):337-48. PubMed ID: 16953517
[TBL] [Abstract][Full Text] [Related]
11. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach.
Nava-Ocampo AA; Koren G
Clin Obstet Gynecol; 2007 Mar; 50(1):123-31. PubMed ID: 17304029
[TBL] [Abstract][Full Text] [Related]
12. Fetal risks of maternal pharmacotherapy: identifying signals.
Koren G
Handb Exp Pharmacol; 2011; 205():285-94. PubMed ID: 21882117
[TBL] [Abstract][Full Text] [Related]
13. Teratological risk evaluation and prevention of voluntary abortion.
De Santis M; Straface G; Cavaliere AF; Cinque B; Carducci B; Caruso A
Minerva Ginecol; 2006 Apr; 58(2):91-9. PubMed ID: 16582865
[TBL] [Abstract][Full Text] [Related]
14. Inactive pharmaceutical ingredients : implications for pregnancy.
Finkelstein Y; Rezvani M; Garcia-Bournissen F; Nurmohamed L; Koren G
Can J Clin Pharmacol; 2007; 14(1):e17-28. PubMed ID: 17213505
[No Abstract] [Full Text] [Related]
15. Collection and analysis of drug safety data in pregnancy.
Moretti M
Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
[No Abstract] [Full Text] [Related]
16. Teratogen risk counselling by internet: a prospective cohort study.
Han JY; Yang JH; Chung JH; Choi JS; Ahn HK; Ryu HM; Kim MY; Cho SI; Nava-Ocampo AA
J Obstet Gynaecol; 2005 Jul; 25(5):427-31. PubMed ID: 16183573
[TBL] [Abstract][Full Text] [Related]
17. [A list of teratogenic human drugs].
Czeizel E; Klujber V
Orv Hetil; 1989 May; 130(19):1022-3. PubMed ID: 2726247
[No Abstract] [Full Text] [Related]
18. Big risks in small groups: The difference between epidemiology and counselling.
Friedman JM
Birth Defects Res A Clin Mol Teratol; 2009 Aug; 85(8):720-4. PubMed ID: 19572407
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium periconceptional exposure: pregnancy and neonatal outcome.
De Santis M; Straface G; Cavaliere AF; Carducci B; Caruso A
Acta Obstet Gynecol Scand; 2007; 86(1):99-101. PubMed ID: 17230297
[TBL] [Abstract][Full Text] [Related]
20. Drugs in pregnancy: acknowledging challenges--finding solutions.
Koren G; MacLeod S; Davis D
Can J Clin Pharmacol; 2007; 14(1):e2-4. PubMed ID: 17213506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
